Moderna PT receives Investment Bank Analyst Rating Update
By Liz Moyer Investing.com -- U.S. stocks accelerated losses heading into the close of trading on Wednesday as investors studied data that showed the economy was cooling. At 16:01...
By Liz Moyer Investing.com -- Stocks fell on Wednesday as investors digested more data that showed a slowing economy. Here are the midday movers for Jan. 18. Microsoft Corporation...
Fed rate hike, U.S. jobs report, more earnings in focus Devon Energy stock is a buy with strong Q3 earnings ahead Robinhood set to struggle amid shrinking revenue, fewer...
If there was an over-arching theme that encapsulated the events related to the markets this week, it was there was no middle of the road. Examples of extremes – as in, the biggest,...
Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The Company develops technologies that enable the development of mRNA medicines.
|Average||226.29 (+19.51% Upside)|
|No. of Analysts||14|